Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report?
- Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/18/2024
|
Amphastar Pharmaceuticals Inc (AMPH) Trading Down 3.54% on Oct 2
- Shares of Amphastar Pharmaceuticals Inc (AMPH, Financial) fell 3.54% in mid-day trading on Oct 2. The stock reached an intraday low of $46.58, before recovering slightly to $46.64, down from its previous close of $48.35.
- 10/02/2024
|
Amphastar Pharmaceuticals Offers Interesting Growth And Income Prospects
- Amphastar Pharmaceuticals shows promising growth potential with its diverse product offerings, including the nasally administered glucagon treatment BAQSIMI and the over-the-counter inhalant Primatene MIST. The company's solid balance sheet, with a current ratio of 3.52 and manageable debt levels, provides flexibility to navigate market changes. Risks include reliance on single-source supplies, dependency on Lilly for BAQSIMI manufacturing, and the impact of reference brand demand on generic products.
- 09/13/2024
|
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
- 08/28/2024
|
6 Beaten Down Stocks Rated Buy (SA Quant)
- The three-week market selloff sparked by recession fears was led by plunging tech, cyclical, industrial, and energy stocks. High-quality stocks clobbered in the past 30 days, and others beaten down in the past year offer potential buying opportunities. We identified 6 stocks down by double digits within the last year with Buy or Strong Buy Quant Ratings, high forward growth metrics, and attractive valuations.
- 08/19/2024
|
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2024 Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer Tony Marrs - Executive Vice President, Regulatory Affairs and Clinical Operations Conference Call Participants Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Jason Gerberry - Bank of America Tim Chiang - Capital One Serge Belanger - Needham & Company Glen Santangelo - Jefferies Operator Greetings, and welcome to the Amphastar Pharmaceuticals Second Quarter Earnings Call. At this time, all participants are in a listen-only mode.
- 08/09/2024
|
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
- The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/07/2024
|
Amphastar Pharmaceuticals (AMPH) Tops Q2 Earnings and Revenue Estimates
- Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.65 per share a year ago.
- 08/07/2024
|
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
- Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 7, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2024. Second Quarter Highlights Net revenues of $182.4 million for the second quarter GAAP net income of $37.9 million, or $0.73 per share, for the second quarter Adjusted non-GAAP net income of $48.7 million, or $0.94 per share, for the second quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "As we finish another strong quarter, Amphastar has continued its impressive performance with solid sales growth.
- 08/07/2024
|
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
- RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 07/31/2024
|
Why Amphastar (AMPH) is Poised to Beat Earnings Estimates Again
- Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/15/2024
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
- 07/10/2024
|
7 Biotech Stocks to Buy on the Dip: June 2024
- Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
- 06/24/2024
|
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
- Will the market get interest rate cuts at all this year? That is the question that looms over most investors' shoulders today.
- 06/18/2024
|
BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC
- TROY, Mich. , June 14, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) as its "Stock to Study" and Medtronic PLC (NYSE: MDT) as its "Undervalued Stock" in the September 2024 issue for investors' informational and educational use.
- 06/14/2024
|
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
- RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.
- 06/04/2024
|
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
- 06/03/2024
|
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
- Seeking Alpha's screener identified Amphastar Pharmaceuticals as a potential investment candidate based on its solid financials, positive growth in revenue and earnings. Despite its strong financials and potential for earnings growth, the company's stock fell 31% in 5 months. The article aims to uncover the reasons behind the price decline to determine if the price decline is a temporary setback that offers an opportunity for value investors.
- 05/30/2024
|
Amphastar Pharmaceuticals: Profitable Pharma With Strong Growth
- Amphastar Pharmaceuticals is a small-cap pharmaceutical company focused on developing and selling injectable, inhalation, and intranasal products. The company reported a 29% increase in net revenues in 2023, driven by sales growth in glucagon, Primatene MIST, epinephrine, and lidocaine. The recent acquisition of BAQSIMI and approval of Rextovy will further expand Amphastar's product portfolio.
- 05/20/2024
|
Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade
- Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden administration is attacking businesses across the board, such as its recent assault on the oil industry.
- 05/16/2024
|
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2024 Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer Conference Call Participants Ekaterina Knyazkova - JPMorgan Timothy Chiang - Capital One Pavan Patel - Bank of America Operator Greetings and welcome to the Amphastar Pharmaceuticals' First Quarter Earnings Call. At this time, all participants are in a listen-only mode.
- 05/08/2024
|
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
- Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.62 per share a year ago.
- 05/08/2024
|
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
- Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 8, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2024. First Quarter Highlights Net revenues of $171.8 million for the first quarter GAAP net income of $43.2 million, or $0.81 per share, for the first quarter Adjusted non-GAAP net income of $55.3 million, or $1.04 per share, for the first quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar's strong first quarter results were led by BAQSIMI ® revenue growth of 22% over what Eli Lilly & Company ("Lilly") reported for the first quarter of 2023.
- 05/08/2024
|
Amphastar Pharmaceuticals (AMPH) Reports Next Week: Wall Street Expects Earnings Growth
- Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/01/2024
|
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
- RANCHO CUCAMONGA, CA / ACCESSWIRE / April 30, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2024 ended March 31, 2024, after the market closes on Wednesday, May 8, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 04/30/2024
|
Why Amphastar (AMPH) Could Beat Earnings Estimates Again
- Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/30/2024
|
New Strong Sell Stocks for April 26th
- AMPH, BCML and DHC have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2024.
- 04/26/2024
|
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / April 1, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9th, 2024 at 3:00 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
- 04/01/2024
|
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 03/27/2024
|
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
- The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $43.21, representing a -0.96% change from its previous close.
- 03/26/2024
|
New Strong Sell Stocks for March 18th
- ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.
- 03/18/2024
|
Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 03/11/2024
|
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, 2024 at 11:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
- 03/06/2024
|
Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
- Amphastar Pharmaceuticals specializes in developing, manufacturing, and distributing pharmaceutical products, with a focus on strategic acquisitions. The company's portfolio includes high-margin products such as Primatene MIST and Glucagon Injection for severe hypoglycemia. Amphastar's pipeline includes promising upcoming products such as Rextovy, and its recent acquisition of Baqsimi enhances its position in diabetes management.
- 03/04/2024
|
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript
- 02/29/2024
|
Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates
- Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.73 per share a year ago.
- 02/28/2024
|
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
- Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2023. Fourth Quarter Highlights Net revenues of $178.1 million for the fourth quarter GAAP net income of $36.2 million, or $0.68 per share, for the fourth quarter Adjusted non-GAAP net income of $46.9 million, or $0.88 per share, for the fourth quarter Full-Year Highlights Net revenues of $644.4 million for the fiscal year GAAP net income of $137.5 million, or $2.60 per share, for the fiscal year Adjusted non-GAAP net income of $175.7 million, or $3.32 per share, for the fiscal year Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We enter 2024 with strong momentum.
- 02/28/2024
|
Amphastar Pharmaceuticals (AMPH) Increases Yet Falls Behind Market: What Investors Need to Know
- In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $51.91, denoting a +1.29% change from the preceding trading day.
- 02/22/2024
|
Wall Street Bulls Look Optimistic About Amphastar (AMPH): Should You Buy?
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 02/22/2024
|
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
- RANCHO CUCAMONGA, CA / ACCESSWIRE / February 20, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 02/20/2024
|
It May Be Time To Revisit Amphastar Once It Settles After A Plunge
- Drug stock Amphastar Pharmaceuticals took a nasty drop in January after nearing highs. It may time to take another look as earnings approach.
- 02/16/2024
|
Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why
- In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $55.61, denoting a +1.85% change from the preceding trading day.
- 02/09/2024
|
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
- The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.
- 02/05/2024
|
Amphastar Pharmaceuticals (AMPH) Falls More Steeply Than Broader Market: What Investors Need to Know
- In the most recent trading session, Amphastar Pharmaceuticals (AMPH) closed at $54.94, indicating a -0.81% shift from the previous trading day.
- 01/30/2024
|
5 Top Growth Stocks to Buy as Recession Fears Subside
- Invest in growth stocks such as Amphastar Pharmaceuticals (AMPH), Abercrombie & Fitch (ANF), Cameco (CCJ), CyberArk Software (CYBR) and LendingTree (TREE) as the U.S. economy defies recession fears.
- 01/26/2024
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.
- 01/25/2024
|
Snap these 4 Top-Ranked Liquid Stocks to Drive Solid Returns
- Here are four top-performing liquid stocks, American Public Education (APEI), Amphastar Pharmaceuticals (AMPH), GigaCloud (GCT) and Oceaneering International (OII), which investors can add to their portfolio to boost returns.
- 01/15/2024
|
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
- Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $54.03, signifying a -1.44% move from its prior day's close.
- 01/11/2024
|
Amphastar Pharmaceuticals (AMPH) Stock Drops Despite Market Gains: Important Facts to Note
- Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $62.74, signifying a -1.12% move from its prior day's close.
- 01/05/2024
|
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 am PST.
- 01/02/2024
|
Amphastar Pharmaceuticals (AMPH) Is Up 1.53% in One Week: What You Should Know
- Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 01/01/2024
|
4 Promising Liquid Stocks to Boost Your Portfolio in 2024
- Building a portfolio comprising stocks with favorable liquidity is the way to go for investors seeking healthy returns.
- 12/29/2023
|
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
- Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.
- 12/26/2023
|
5 Good Opportunities on Relative Price Strength Strategy
- AMPH, FOUR, BECN, HOFT and HTH are five stocks with explosive relative price strength.
- 12/26/2023
|
3 Stocks at the Forefront of Medical Innovation
- Innovation in the medical world is undoubtedly a fundamental pillar in the development of humanity. There are great companies within the biotech sector doing wonderful work, research, and developments, not only to attack important diseases but also to prevent them.
- 12/25/2023
|
3 Reasons Why Amphastar (AMPH) Is a Great Growth Stock
- Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 12/25/2023
|
What's in Store for Nasdaq in 2024? 5 Top Picks
- After a strong 2023, we expect the Nasdaq to log gains in 2024. Top-ranked Nasdaq stocks GigaCloud Technology Inc (GCT), Carrols Restaurant Group (TAST), Limbach (LMB), Amphastar Pharmaceuticals (AMPH) and Insight Enterprises Inc (NSIT) could emerge as winning picks.
- 12/12/2023
|
Snap These 4 Top-Performing Liquid Stocks for Strong Returns
- Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX) and GigaCloud Technology Inc. (GCT), which investors can add to their portfolio for solid gains.
- 12/11/2023
|
3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH)
- Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.
- 12/08/2023
|
Are You Looking for a Top Momentum Pick? Why Amphastar Pharmaceuticals (AMPH) is a Great Choice
- Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 12/05/2023
|
3 Best Momentum Stocks to Buy Using the Driehaus Strategy
- Stocks like Abercrombie & Fitch (ANF), Amphastar Pharmaceuticals (AMPH) and NetEase (NTES) have been selected as the momentum picks for the day using the Driehaus strategy.
- 12/05/2023
|
This Biotech Stock Nears A Buy Point After 200% Profit Growth
- This biotech stock is in a base after the company produced triple-digit earnings growth. AMPH stock is poised for a move.
- 11/30/2023
|
4 Top-Performing Liquid Stock Picks for Robust Returns
- Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX), and Vimeo (VMEO), which investors can add to their portfolio for solid gains.
- 11/30/2023
|
3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH)
- Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.
- 11/22/2023
|
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / November 20, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am EST.
- 11/20/2023
|
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / November 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi EVP of Corp. Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 2:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
- 11/09/2023
|
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2023 Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Dan Dischner - SVP of Corporate Communications Bill Peters - CFO Conference Call Participants Glen Santangelo - Jefferies Tim Chiang - Capital One Operator Greetings and welcome to the Amphastar Pharmaceuticals Third Quarter Earnings Conference Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for future periods are forward-looking statements.
- 11/08/2023
|
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
- RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2023 ended September 30, 2023, after the market closes on Wednesday, November 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 11/01/2023
|
Amphastar Pharmaceuticals (AMPH) Rises Yet Lags Behind Market: Some Facts Worth Knowing
- In the most recent trading session, Amphastar Pharmaceuticals (AMPH) closed at $45.27, indicating a +0.2% shift from the previous trading day.
- 10/31/2023
|
Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why
- The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $45.19, representing a +1.23% change from its previous close.
- 10/30/2023
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.
- 10/30/2023
|
Amphastar Pharmaceuticals (AMPH) Rises As Market Takes a Dip: Key Facts
- In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $44.72, denoting a +0.52% change from the preceding trading day.
- 10/23/2023
|
Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why
- Amphastar Pharmaceuticals (AMPH) closed at $46.47 in the latest trading session, marking a +1.55% move from the prior day.
- 10/16/2023
|
Amphastar Pharmaceuticals: Great Growth At A High Price
- Amphastar Pharmaceuticals has implemented aggressive corporate strategies to maximize margins and increase sales, resulting in impressive EBIT and revenue growth. The company's focus on high-margin products and strategic acquisitions has contributed to its success. While the company's growth prospects and pipeline are promising, the current share price may pose a risk for investors.
- 10/10/2023
|
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
- Here is how Amphastar Pharmaceuticals (AMPH) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
- 10/10/2023
|
Amphastar Pharmaceuticals (AMPH) Rises Higher Than Market: Key Facts
- In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $47.55, denoting a +0.76% change from the preceding trading day.
- 10/09/2023
|
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / August 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Wells Fargo Healthcare Conference on September 7, 2023 at 12:45 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
- 08/31/2023
|
Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why
- Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.
- 08/18/2023
|
Is Amphastar (AMPH) a Solid Growth Stock? 3 Reasons to Think "Yes"
- Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.
- 08/11/2023
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.
- 08/11/2023
|
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
- Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.39 per share a year ago.
- 08/08/2023
|
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2023 Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications Bill Peters - Chief Financial Officer & Executive Vice President, Finance Tony Marrs - Executive Vice President, Regulatory Affairs & Clinical Operations Conference Call Participants Tim Chiang - Capital One David Amsellem - Piper Sandler Operator Greetings and welcome to the Amphastar Pharmaceuticals Second Quarter Earnings Call. At this time, all participants are in a listen-only mode.
- 08/08/2023
|
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
- RANCHO CUCAMONGA, CA / ACCESSWIRE / August 2, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2023 ended June 30, 2023, after the market closes on Tuesday, August 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 08/02/2023
|
Amphastar Pharmaceuticals (AMPH) is a Great Momentum Stock: Should You Buy?
- Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/26/2023
|
5 Must-Buy High-Flying Mid-Caps to Enhance Your Portfolio
- We have narrowed our search to five mid-cap stocks with more than 50% returns year to date. These are: PGTI, SHAK, IDCC, ANF, AMPH.
- 07/19/2023
|
Amphastar (AMPH) is an Incredible Growth Stock: 3 Reasons Why
- Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 07/12/2023
|
3 Profitable Stocks Worth Investing in Using Net Income Ratio
- PDD Holdings (PDD), Amphastar Pharmaceuticals (AMPH) and Suzano (SUZ) are some of the top picks with a high net income ratio.
- 07/07/2023
|
Amphastar Pharmaceuticals (AMPH) Is Up 0.54% in One Week: What You Should Know
- Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/05/2023
|
Promising Small Biotech Amphastar Sees Actionable Pullback
- Amphastar Pharmaceuticals Inc. NASDAQ: AMPH, a small cap that's one of the leading performers within the biotech space, is forming an orderly pullback and is currently actionable as it holds above its 10-day moving average.
- 06/28/2023
|
3 Reasons Growth Investors Will Love Amphastar (AMPH)
- Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 06/26/2023
|
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
- Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
- 06/23/2023
|
4 Top-Ranked Profitable Stocks to Buy Using Net Income Ratio
- PDD Holdings Inc. (PDD), Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH) and Axon Enterprise (AXON) have been selected as the top picks with a high net income ratio.
- 06/20/2023
|
Here is Why Growth Investors Should Buy Amphastar (AMPH) Now
- Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.
- 06/08/2023
|
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
- Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
- 06/07/2023
|
4 Solid Profitable Stocks to Invest in Using Net Income Ratio
- Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH), Turkcell Iletisim Hizmetleri (TKC) and Copa Holdings (CPA) have been selected as the top picks with a high net income ratio.
- 06/02/2023
|
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / May 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Jefferies Healthcare Conference on June 8, 2023 at 2:30 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
- 05/31/2023
|
Looking for a Growth Stock? 3 Reasons Why Amphastar (AMPH) is a Solid Choice
- Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.
- 05/23/2023
|
3 Generic Drug Stocks to Watch Amid Macro Headwinds
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
- 05/23/2023
|
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
- Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
- 05/22/2023
|
Amphastar (AMPH) Is a Great Choice for 'Trend' Investors, Here's Why
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Amphastar (AMPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 05/22/2023
|
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2023 Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Dan Dischner - VP of HR & Corporate Communication William Peters - CFO, Executive VP of Finance, Treasurer & Director Conference Call Participants Tim Chiang - Capital One David Amsellem - Piper Sandler Operator Greetings, and welcome to the Amphastar Pharmaceuticals, Inc. First Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for future periods are forward-looking statements.
- 05/13/2023
|
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
- Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.47 per share a year ago.
- 05/09/2023
|
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
- RANCHO CUCAMONGA, CA / ACCESSWIRE / May 3, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2023 ended March 31, 2023, after the market closes on Tuesday, May 9, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 05/03/2023
|
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
- Here is how Amphastar Pharmaceuticals (AMPH) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
- 04/26/2023
|
Eli Lilly to sell Baqsimi diabetes drug to Amphastar for around $1 billion
- Eli Lilly and Co (NYSE:LLY) revealed that it will sell Baqsimi, its nasal treatment for severe hypoglycemia in people with diabetes, to Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for around $1 billion. The Indianapolis, Indiana-based company has signed a definitive agreement to divest Baqsimi worldwide to Amphastar for $500 million in cash at closing and an additional $125 million in cash upon the one-year anniversary of closing.
- 04/24/2023
|
Eli Lilly to sell hypoglycemia treatment for up to $1.1 billion in cash and milestone payments to Amphastar
- Shares of Eli Lilly & Co. LLY gained 0.5% in premarket trading Monday, after the drugmaker announced an agreement to sell its hypoglycemia treatment for people with diabetes Baqsimi to Amphastar Pharmaceuticals Inc. AMPH for up to $1.075 billion in cash and potential milestone payments. Under terms of the agreement, Amphastar will pay $500 million in cash upfront and another $125 million in cash one year after the deal closes, which is expected to occur in the third quarter of 2023.
- 04/24/2023
|
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
- RANCHO CUCAMONGA, CA / ACCESSWIRE / April 24, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will provide a Business update and hold a Conference call today, Monday, April 24, 2023, at 6:00 am Pacific Time. To access the conference call, please dial 877-407-0989, or for international callers, please dial +1 201-389-0921, five minutes before the conference begins.
- 04/24/2023
|
3 Profitable Stocks Worth a Buy Using Net Income Ratio
- Amphastar Pharmaceuticals (AMPH), Alpha Metallurgical Resources (AMR) and Riley Exploration Permian (REPX) have been selected as the top picks with a high net income ratio.
- 04/21/2023
|
Amphastar Pharmaceuticals Drug Stock Nears All-Time High After 74% Earnings Growth
- This drug stock gained 35% since its earnings report. The biotech got FDA approval for its opioid overdose nasal spray.
- 04/20/2023
|
Strength Seen in Amphastar (AMPH): Can Its 6.4% Jump Turn into More Strength?
- Amphastar (AMPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 04/14/2023
|
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / April 12, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Jacob Liawatidewi, EVP of Corporate Administration, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 19th, 2023 at 12:45 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
- 04/12/2023
|
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 03/24/2023
|
Amphastar Pharmaceuticals (AMPH)'s Technical Outlook is Bright After Key Golden Cross
- When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
- 03/13/2023
|
2 Stocks to Buy Now After Powell Flips the Narrative
- Expectations for the next FOMC meeting have seen odds of a 50bps rate hike go from extremely unlikely to highly likely
- 03/09/2023
|
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
- Here is how Amphastar Pharmaceuticals (AMPH) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
- 03/08/2023
|
3 Generic Drug Stocks to Watch Amid Macro Headwinds
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
- 03/03/2023
|
Why Shares of Amphastar Pharmaceuticals Rose Today
- The company reported a record revenue year and increased EPS.
- 03/01/2023
|
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 92.11% and 6.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2023
|
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2022 Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Bill Peters - Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of IMS Ltd., and Director Dan Dischner - VP of Human Resources and Corporate Communication Tony Marrs - Sr. VP of Regulatory Affairs and Sr. VP of Clinical Operations Conference Call Participants Timothy Chiang - Capital One David Amsellem - Piper Sandler Operator Greetings, and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings Call.
- 02/28/2023
|
Amphastar: Generating High Incremental Growth From Tidy Earnings Reinvestment
- Amphastar stock has generated high rates of post-tax earnings growth with small increments of additional capital investment since FY20. The incremental returns on capital are above historical returns on capital, illustrating the profitability of recent product launches over the legacy portfolio.
- 02/09/2023
|
3 Generic Drug Stocks to Watch Amid Inflation Pressures
- The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
- 12/07/2022
|
Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 30th, 2022 at 11:00 am Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
- 11/22/2022
|
Amphastar: Growth Remains Intact
- Quarter-over-Quarter growth in revenue has persisted due to the consistent launch of new product pipelines. The overall financial position is substantially strong, which offers significant flexibility for the company.
- 11/14/2022
|
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2022 Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q3 2022 Results Conference Call November 7, 2022 5:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Peters - Chief Executive Officer Dan Dischner - Vice President of Corporate Communications Tony Marrs - Senior Vice President of Regulatory Affairs and Clinical Operations Conference Call Participants David Amsellem - Piper Sandler Serge Belanger - Needham & Company Elliot Wilbur - Raymond James Operator Greetings, and welcome to the Amphastar Pharmaceuticals, Inc. Third Quarter Earnings Call. At this time, all participants are in a listen-only mode.
- 11/07/2022
|
Amphastar Pharmaceuticals (AMPH) Q3 Earnings Meet Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 0% and 4.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/07/2022
|
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022
- RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 2022, after the market closes on Monday, November 7, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 10/28/2022
|
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
- Here is how Amphastar Pharmaceuticals (AMPH) and Haemonetics (HAE) have performed compared to their sector so far this year.
- 10/10/2022
|
Amphastar: A Pharmaceutical Growth Stock
- Amphastar's profitability and cash flow have been increasing consistently, and with management's efforts, profitability will increase significantly. Having a solid financial position and consistent growth will eventually lead to a more sustainable business model, and in such cases, valuation will not remain at this level.
- 10/06/2022
|
7 Safe Stocks to Rely on When the Market Swerves
- Back in August, I made the argument why now's the right time to buy safe stocks. Just over a month later, this continues to be the case.
- 09/19/2022
|
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sales and Marketing and Tony Marrs Sr. Vice President of Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Wells Fargo 2022 Healthcare Conference on September 7th, 2022 at 1:20 pm Eastern Standard Time.
- 09/02/2022
|
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q2 2022 Results - Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2022 Results Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Peters - Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of International Medication Systems, Ltd. Tony Marrs - Senior Vice President, Regulatory Affairs Conference Call Participants Tim Chiang - Capital One Elliot Wilbur - Raymond James Serge Belanger - Needham & Company, LLC David Amsellem - Piper Jaffray Operator Greetings and welcome to the Amphastar Pharmaceuticals Second Quarter Earnings Call.
- 08/08/2022
|
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 5.41% and 4.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/08/2022
|
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill
- Amphastar and Syndax, two top-rated biotech stocks, topped second-quarter estimates on Tuesday. But shares stayed flat.
- 08/08/2022
|
Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
- Amphastar currently has seven drugs under development, two drugs awaiting launch, and a base of over nine FDA-approved products in production. With the recent approval of generic ganirelix and vasopressin, which have a TAM of $850 million, AMPH could nearly double its revenue by YE 2023 with proper execution.
- 08/08/2022
|
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022
- RANCHO CUCAMONGA, CA / ACCESSWIRE / August 1, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022, after the market closes on Monday, August 8, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 08/01/2022
|
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
- Amphastar Pharmaceutcls is near a buy zone with earnings due on or around Aug. 9. The post Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings appeared first on Investor's Business Daily.
- 07/26/2022
|
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate Communications, will be presenting at the Jefferies Healthcare Conference on June 8, 2022 at 8:00 am Eastern Standard Time.
- 06/06/2022
|
Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
- Amphastar Pharmaceuticals has several key growth drivers: a strong pipeline of products currently awaiting approval, exciting products with growing sales, and growing marketing and distribution channels. With approvals for its developed products pending, AMPH could anticipate doubling its revenues if it can obtain those approvals on time.
- 05/13/2022
|
7 Safe Small-Cap Stocks to Buy Now
- If you're looking for resilient plays with high upside potential, consider these seven safe small-cap stocks to buy. The post 7 Safe Small-Cap Stocks to Buy Now appeared first on InvestorPlace.
- 05/12/2022
|
Has Amphastar Pharmaceuticals (AMPH) Outpaced Other Medical Stocks This Year?
- Here is how Amphastar Pharmaceuticals (AMPH) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
- 05/11/2022
|
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 42.42% and 8.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/09/2022
|
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q1 2022 Results - Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Dan Dischner - VP, Corporate Communications Bill Peters - CFO Conference Call Participants Elliot Wilbur - Raymond James David Amsellem - Piper Sandler Tim Chiang - Northland Securities Operator Greetings, and welcome to the Amphastar Pharmaceuticals Incorporated First Quarter Earnings Call. At this time, all participants are in a listen-only mode.
- 05/09/2022
|
Is a Surprise Coming for Amphastar Pharmaceuticals (AMPH) This Earnings Season?
- Amphastar Pharmaceuticals (AMPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/04/2022
|
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022
- RANCHO CUCAMONGA, CA / ACCESSWIRE / May 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2022 ended March 31, 2022, after the market closes on Monday, May 9th 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 05/02/2022
|
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
- The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
- 05/02/2022
|
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?
- Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2022
|
Can Amphastar (AMPH) Keep the Earnings Surprise Streak Alive?
- Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/22/2022
|
10 Stocks That Have Moved Over 20% Since The Indices Lost Over 12%!
- The start of 2022 saw a decline in the stock market. For seasoned investors, this was not unexpected, as corrections in the market are commonplace from January through to March.
- 04/08/2022
|
Amphastar Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / April 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P.
- 04/06/2022
|
7 “A”-Rated Stocks to Ground Your Portfolio
- It's a good time to make sure you have "A"-rated stocks in your portfolio. Many of the ones here have my triple-"A" rating.
- 03/17/2022
|
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q4 2021 Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q4 2021 Earnings Call Transcript
- 03/10/2022
|
Amphastar Pharmaceuticals (AMPH) Tops Q4 Earnings and Revenue Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 10.53% and 8.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/10/2022
|
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 10th, 2022
- RANCHO CUCAMONGA, CA / ACCESSWIRE / March 3, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2021 ended December 31, 2021, after the market closes on Thursday, March 10th, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 03/03/2022
|
S&P 500 Stocks With Strong Momentum
- We identified 18 stocks in S&P 500 with strong momentum based on our criteria. Ten of the stocks we identified made new all-time highs.
- 02/13/2022
|
7 Safe Stocks to Rely On When the Market Swerves
- When markets that have flown so high for so long start to tumble, along with an economy that transitioning, safe stocks are essential. The post 7 Safe Stocks to Rely On When the Market Swerves appeared first on InvestorPlace.
- 02/09/2022
|
Amphastar Pharma: A Well-Run, Diversified Mid Cap
- Amphastar has a unique combo of a development stage and a more mature biotech company. It is well placed in growing but competitive areas of medicine like diabetes and asthma.
- 01/25/2022
|
3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure
- The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.
- 12/29/2021
|
Sail Through the Choppy Market With These 3 Low-Beta Stocks
- It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. Amphastar (AMPH), Sanderson Farms (SAFM) and Sensus Healthcare (SRTS) are well poised to gain.
- 12/16/2021
|
3 Stocks With Low PEG Ratios
- When screening the market for bargain opportunities, investors may want to look for stocks whose trailing 12-month and forward price-earnings to growth (PEG) ratios are at or below 1.5 as of Dec. 13, which is the S&P 500's historical average PEG ratio.
- 12/14/2021
|
Why You Shouldn't Bet Against Amphastar Pharmaceuticals (AMPH) Stock
- Amphastar Pharmaceuticals (AMPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 12/07/2021
|
Bet on These 3 Low-Beta Stocks to Combat Market Volatility
- It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Amphastar Pharmaceuticals (AMPH), AMN Healthcare (AMN) & Sensus Healthcare (SRTS) are well poised to gain.
- 12/02/2021
|
Amphastar Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P.
- 11/22/2021
|
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / November 11, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P.
- 11/11/2021
|
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2021 Results - Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2021 Results - Earnings Call Transcript
- 11/08/2021
|
Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Beat Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 109.09% and 8.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2021
|
Amphastar Pharmaceuticals: Q3 Earnings Insights
- Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q3 earnings results on Monday, November 8, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
- 11/08/2021
|
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: What to Know Ahead of Q3 Release
- Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/29/2021
|
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8th, 2021
- RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2021 ended September 30, 2021, after the market closes on Monday, November 8, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 10/28/2021
|
Amphastar Pharmaceuticals to Present at the Wells Fargo 2021 Virtual Healthcare Conference
- RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P.
- 09/02/2021
|
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
- The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
- 08/17/2021
|
Amphastar Pharmaceuticals, Inc. (AMPH) on Q2 2021 Results - Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (AMPH) on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Amphastar Pharmaceuticals (AMPH) Meets Q2 Earnings Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 0.00% and 0.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021
- Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 9, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2021. Second Quarter Highlights Net revenues of $101.7 million for the second quarter GAAP net income of $7.8 million, or $0.16 per share, for the second quarter Adjusted non-GAAP net income of $10.6 million, or $0.21 per share, for the second quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Continued strong sales of glucagon, Primatene Mist® and our epinephrine products led to another strong quarter of growth.
- 08/09/2021
|
Amphastar Pharmaceuticals (AMPH) to Report Q2 Results: Wall Street Expects Earnings Growth
- Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2021
|
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9th, 2021
- RANCHO CUCAMONGA, CA / ACCESSWIRE / July 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2021 ended June 30, 2021, after the market closes on Monday, August 9th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 07/29/2021
|
Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference
- RANCHO CUCAMONGA, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will be presenting at the Human Health Innovation Conference on Tuesday, June 22, 2021, at 2:00 pm Eastern time.
- 06/15/2021
|
Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
- RANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:30 pm Eastern time.
- 05/27/2021
|
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q1 2021 Results - Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary
- RANCHO CUCAMONGA, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). As part of the restructuring, Amphastar will buyback 26% of ANP's equity currently held by third parties. In addition, ANP will spin-off its Chinese subsidiary, Nanjing Hanxin Pharmaceutical Technology Co., Ltd. and Hanxin's subsidiaries (collectively, “Hanxin”). The restructuring is subject to regulatory approval, and the total cash payment by Amphastar for this restructuring will be approximately $29 million.
- 05/07/2021
|
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 42.11% and 6.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
Recap: Amphastar Pharmaceuticals Q1 Earnings
- Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.82% over the past year to $0.27, which beat the estimate of $0.18.
- 05/06/2021
|
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021
- Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021
- 05/06/2021
|
Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection
- RANCHO CUCAMONGA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company's Abbreviated New Drug Application (“ANDA”) for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet® Prefilled Syringe System. It is indicated for the management of pain severe enough to require use of an opioid analgesic by Patient-Controlled Analgesia (PCA), only for use with a compatible Alaris® infusion device, and for which alternative treatments are inadequate. For the past 30 years, the company has sold and marketed the product under the “grandfather” exception to the FDA's “Prescription Drug Wrap-Up” program. Net revenues for the Company's Morphine injection for the year ended December 31, 2020, were $2.3 million.
- 05/03/2021
|
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021
- RANCHO CUCAMONGA, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2021 ended March 31, 2021, after the market closes on Thursday, May 6th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 04/29/2021
|
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
- 3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
- 04/14/2021
|
AMPH Stock Price Increased Over 5% Pre-Market: Why It Happened
- The stock price of Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) increased by over 5% pre-market. This is why it happened.
- 03/29/2021
|
Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
- RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company's Abbreviated New Drug Application (“ANDA”) for Dextrose injection 50% in the 50 mL Luer-Jet® Prefilled Syringe System. For the past 40 years, the company has sold and marketed the product under the “grandfather” exception to the FDA's “Prescription Drug Wrap-Up” program. Net revenues for the Company's Dextrose injection for the year ended December 31, 2020, were $7.6 million.
- 03/29/2021
|
New Strong Sell Stocks for March 18th
- Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
- 03/18/2021
|
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q4 2020 Results - Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q4 2020 Results - Earnings Call Transcript
- 03/15/2021
|
Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 14.29% and 7.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/15/2021
|
Recap: Amphastar Pharmaceuticals Q4 Earnings
- Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 128.57% year over year to $0.16, which beat the estimate of $0.14.
- 03/15/2021
|
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020
- Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020
- 03/15/2021
|
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021
- RANCHO CUCAMONGA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
- 03/08/2021
|
Amphastar Pharmaceuticals to Present at the Raymond James 2021 Institutional Healthcare Conference
- RANCHO CUCAMONGA, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Raymond James 2021 Institutional Healthcare Conference on Tuesday, March 2, 2021 at 1:20 pm Eastern time.
- 02/26/2021
|
Amphastar Announces Approval for Glucagon for Injection Kit, 1mg
- RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. Amphastar's newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly's Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin.
- 12/29/2020
|
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2020 Results - Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2020 Results - Earnings Call Transcript
- 11/08/2020
|
Amphastar Pharmaceuticals' (AMPH) Management on Q3 2020 Results - Quick Version Earnings Call Transcript
- Amphastar Pharmaceuticals' (AMPH) Management on Q3 2020 Results - Quick Version Earnings Call Transcript
- 11/06/2020
|
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020
- Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020 Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020
- 11/06/2020
|
Preclinical Respiration and Inhalation Lab Equipment Market: COVID-19 Business Continuity Plan | Evolving Opportunities with 4DMedical Ltd and CH Technologies USA Inc. | Technavio
- The Global Preclinical Respiration and Inhalation Lab Equipment Market will grow by $ 2.26 mn during 2020-2024
- 09/15/2020
|
Amphastar Pharmaceuticals (AMPH) Presents at Wells Fargo Securities 2020 Virtual Healthcare Conference - Slideshow
- The following slide deck was published by Amphastar Pharmaceuticals, Inc. in conjunction with this event..
- 09/11/2020
|
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2020
- Reports Net Revenues of $85.8 Million for the Three Months Ended June 30, 2020RANCHO CUCAMONGA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2020. Second Quarter Highlights * Net revenues of $85.8 million for the second quarter * GAAP net loss of $0.2 million, or $0.00 per share, for the second quarter * Adjusted non-GAAP net income of $7.6 million, or $0.16 per share, for the second quarterDr. Jack Zhang, Amphastar’s President and Chief Executive Officer, commented: “We are pleased with Amphastar’s second quarter and the first half of the year so far. Primatene® Mist has been a strong performer for the Company, while our epinephrine multi-dose vial launch continues to gain momentum. Despite the challenges presented by the COVID-19 pandemic, we remain confident, heading into our catalyst-rich second half of the year.” Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 (in thousands, except per share data) Net revenues $ 85,806 $ 79,047 $ 170,494 $ 158,837 GAAP net (loss) income attributable to Amphastar $ (192) $ 47,787 $ 3,757 $ 48,655 Adjusted non-GAAP net income attributable to Amphastar* $ 7,610 $ 4,117 $ 15,993 $ 9,002 GAAP diluted EPS attributable to Amphastar shareholders $ (0.00) $ 0.96 $ 0.08 $ 0.97 Adjusted non-GAAP diluted EPS attributable to Amphastar shareholders* $ 0.16 $ 0.08 $ 0.33 $ 0.18 _______________________________ * Adjusted non-GAAP net income attributable to Amphastar and Adjusted non-GAAP diluted EPS attributable to Amphastar shareholders are non-GAAP financial measures. Please see the discussion in the section entitled “Non-GAAP Financial Measures” and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.Second Quarter Results Three Months Ended June 30, Change 2020 2019 Dollars % (in thousands) Net revenues: Primatene® Mist $ 12,468 $ 2,512 $ 9,956 396 % Phytonadione 10,689 12,441 (1,752) (14)% Enoxaparin 10,218 9,838 380 4 % Lidocaine 7,608 10,082 (2,474) (25)% Naloxone 8,723 7,833 890 11 % Epinephrine 6,957 3,139 3,818 122 % Other finished pharmaceutical products 24,272 27,890 (3,618) (13)% Total finished pharmaceutical products net revenues $ 80,935 $ 73,735 $ 7,200 10 % API 4,871 5,312 (441) (8)% Total net revenues $ 85,806 $ 79,047 $ 6,759 9 % Changes in net revenues were primarily driven by: * Increased sales of Primatene® Mist primarily resulting from the continued success of our nationwide television, radio, and digital marketing campaign * Increased epinephrine sales due to the launch of our newly-approved epinephrine injection, USP 30mg/30mL multiple-dose vial product as well as increased sales of our epinephrine pre-filled syringes * Increased naloxone sales due to higher unit volumes * Decreased lidocaine sales due to lower demand, largely due to reductions in elective procedures, in which the jelly form of lidocaine is often used, during the COVID-19 pandemic * Decreases in other finished pharmaceutical products were driven by reductions in products frequently used in elective procedures including Cortrosyn®, which were partially offset by an increase in sodium bicarbonate as we were able to utilize our new production line approved earlier in the year to meet strong demand Three Months Ended June 30, Change 2020 2019 Dollars % (in thousands) Net revenues $ 85,806 $ 79,047 $ 6,759 9% Cost of revenues 52,629 46,660 5,969 13% Gross profit $ 33,177 $ 32,387 $ 790 2% as % of net revenues 39% 41% Changes in cost of revenues and the resulting decrease to gross margin were primarily driven by: * Increase in inventory reserves including a $3.6 million reserve for crude heparin purchases and commitments at our Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Inc. * Increased sales of Primatene® Mist and the launch of epinephrine injection multiple-dose vial, both of which have higher margins, partially offset the inventory reserves Three Months Ended June 30, Change 2020 2019 Dollars % (in thousands) Selling, distribution and marketing $ 4,026 $ 2,992 $ 1,034 35% General and administrative 15,924 12,426 3,498 28% Research and development 16,149 15,996 153 1% * Marketing and distribution expenses increased primarily related to Primatene® Mist, including the cost of a national digital, television, radio and digital marketing campaign, which began in July 2019 * General and administrative expenses increased primarily due to the separation agreement entered into with a former executive, in which we incurred an expense of $4.9 million relating to cash compensation and share-based compensation expense * Research and development expenses increased primarily at our ANP subsidiary Three Months Ended June 30, Change 2020 2019 Dollars % (in thousands) Non-operating income (expense), net $ 1,418 $ 60,120 $ (58,702) NM * In June 2019, we recognized a gain of $59.9 million relating to the settlement of our patent and antitrust litigation with Momenta Pharmaceuticals, Inc. and Sandoz Inc.Cash flow provided by operating activities for the six months ended June 30, 2020, was $31.6 million.Impact of COVID-19The increase in sales of Primatene® Mist and certain hospital products as a result of the COVID-19 pandemic experienced towards the end of the first quarter continued into the early part of the second quarter of 2020. We also noticed a decline in demand for certain products such as Cortrosyn® and lidocaine, which are frequently used in elective procedures. The Company has not experienced any significant negative impacts on its cash flows or operations as a result of the COVID-19 pandemic. All of the Company’s production facilities continued to operate during the quarter as they had prior to the COVID-19 pandemic with very little change, other than for enhanced safety measures intended to prevent the spread of the virus. It is not possible at this time to estimate the complete impact that the COVID-19 pandemic could have on our business, as the impact will depend on future developments of the pandemic, which are highly uncertain and cannot be predicted.Share Buyback ProgramOn August 4, 2020, the Company’s Board of Directors authorized an increase of $20 million to the Company’s share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs.Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company’s management and in accordance with the requirements of the Securities and Exchange Commission and applicable laws.The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.Pipeline Information The Company currently has five ANDAs filed with the FDA targeting products with a market size of approximately $1.7 billion, three biosimilar products in development targeting products with a market size of approximately $13 billion, and nine generic products in development targeting products with a market size of approximately $12 billion. This market information is based on IQVIA data for the 12 months ended June 30, 2020. The Company is currently developing four proprietary products, including a new drug application for intranasal naloxone.Amphastar’s Chinese subsidiary, ANP, currently has 14 Drug Master Files, or DMFs, on file with the FDA and is developing several additional DMFs.Company Information Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.Amphastar’s logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, Primatene®, Amphadase® and Cortrosyn®, are the property of Amphastar.Non-GAAP Financial Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP.
- 08/06/2020
|
Amphastar Pharmaceuticals's Earnings: A Preview
- On Thursday, August 06, Amphastar Pharmaceuticals (NASDAQ: AMPH) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.Earnings and Revenue Analysts expect Amphastar Pharmaceuticals earnings of $0.14 per share. Revenue will likely be around $86.62 million, according to the consensus estimate. In the same quarter last year, Amphastar Pharmaceuticals reported EPS of $0.080 on revenue of $79.05 million. If the company were to match the consensus estimate, earnings would be up 75.0%. Amphastar Pharmaceuticals's reported EPS has stacked up against analyst estimates in the past like this:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate 0.08 0.07 0.07 0.03 EPS Actual 0.17 0.07 0.10 0.08 Revenue Estimate 82.83 M 81.79 M 78.53 M 77.61 M Revenue Actual 84.69 M 83.38 M 80.14 M 79.05 M Stock Performance Over the last 52-week period, shares are down 1.19%. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.View more earnings on AMPHDon't be surprised to see the stock move on comments made during its conference call. Amphastar Pharmaceuticals is scheduled to hold the call at 17:00:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/h94bi5cqSee more from Benzinga * Earnings Outlook For Appian * Earnings Preview for American Vanguard * Alteryx Earnings Preview(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/05/2020
|
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Short Interest Down 6.7% in July
- Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) was the target of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 2,630,000 shares, a decrease of 6.7% from the June 30th total of 2,820,000 shares. Based on an average trading volume of 347,100 shares, the days-to-cover ratio is […]
- 08/04/2020
|
Here's What Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Shareholder Ownership Structure Looks Like
- If you want to know who really controls Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), then you'll have to look at the...
- 08/03/2020
|
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6th, 2020
- RANCHO CUCAMONGA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2020 ended June 30, 2020, after the market closes on Thursday, August 6th, 2020, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (800) 708-4540, five minutes before the conference. The passcode for the conference call is 49844225.The call can also be accessed on the Investors page on the Company’s website www.amphastar.com.Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.Forward Looking StatementsAll statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 16, 2020. In particular, the extent of COVID-19’s impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar’s expectations to change. Contact:William J. Peters Chief Financial Officer (909) 980-9484
- 07/30/2020
|
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?
- Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2020
|
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Stock Holdings Lifted by AQR Capital Management LLC
- AQR Capital Management LLC lifted its position in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 130.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 88,846 shares of the company’s stock after acquiring an additional 50,278 shares during the period. AQR Capital […]
- 07/04/2020
|
Are Robust Financials Driving The Recent Rally In Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock?
- Amphastar Pharmaceuticals (NASDAQ:AMPH) has had a great run on the share market with its stock up by a significant 48...
- 07/03/2020
|
Needham Downgrades Zynerba Pharmaceuticals (ZYNE) to Hold - Markets
- In a report released today, Serge Belanger from Needham downgraded Zynerba Pharmaceuticals (ZYNE – Research Report) to Hold. The company’s
- 07/01/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on G1 Therapeutics
- 07/01/2020
|
Northland Securities Maintains a Buy Rating on Verrica Pharmaceuticals (VRCA) - Markets
- Northland Securities analyst Tim Chiang maintained a Buy rating on Verrica Pharmaceuticals (VRCA – Research Report) today and set a
- 06/30/2020
|
Analysts Are Bullish on These Healthcare Stocks: Verrica Pharmaceuticals (VRCA), Intercept Pharma (ICPT) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verrica Pharmaceuticals
- 06/30/2020
|
Needham Assigns a Buy Rating on Zogenix (ZGNX) - Markets
- In a report released today, Serge Belanger from Needham assigned a Buy rating to Zogenix (ZGNX – Research Report), with
- 06/29/2020
|
Collegium Pharmaceutical (COLL) Gets a Buy Rating from Needham - Markets
- In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report),
- 06/26/2020
|
Aerie Pharma (AERI) Gets a Buy Rating from Needham - Markets
- In a report released today, Serge Belanger from Needham assigned a Buy rating to Aerie Pharma (AERI – Research Report),
- 06/26/2020
|
Collegium Pharmaceutical (COLL) Gets a Buy Rating from Needham - Markets
- In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report),
- 06/19/2020
|
Needham Maintains a Buy Rating on Aerie Pharma (AERI) - Markets
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report),
- 06/19/2020
|
Amphastar Pharmaceuticals to Present at the BMO Prescriptions for Success Healthcare Conference
- Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
- 06/19/2020
|
$84.30 Million in Sales Expected for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) This Quarter
- Equities research analysts expect that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will post sales of $84.30 million for the current quarter, Zacks reports. Four analysts have issued estimates for Amphastar Pharmaceuticals’ earnings. The lowest sales estimate is $76.50 million and the highest is $89.20 million. Amphastar Pharmaceuticals posted sales of $79.05 million during the same quarter last […]
- 06/15/2020
|
Amphastar Pharmaceuticals Inc (AMPH): Hedge Funds In Wait-and-See Mode
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- 06/12/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row - Markets
- After Mizuho Securities and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy,
- 06/12/2020
|
Amphastar Pharmaceuticals to Present at the Raymond James Virtual 2020 Human Healthcare Innovation Conference
- Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at the Raymond James Virtual 2020 Human Healthcare Innovation Conference on Thursday, June 18, 2020 at 11:40 a.m. Eastern Time. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
- 06/12/2020
|
Top Pharmaceutical Stocks for Q3 2020
- These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2020.
- 06/11/2020
|
Dow Jones Today Set To Snap Win Streak, Stocks Lower As Airline Pullback: Dexcom Rallies On Price Hike
- Lovesac and Nikola were early risers, as airlines retreated and stock futures slipped and the Dow Jones today appeared set to snap its seven-day advance.
- 06/09/2020
|
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial
|
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial
- Amphastar’s newly approved drug product was determined by the FDA to be therapeutically equivalent to Quelicin™ (Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial) distributed in the United States by Pfizer, Inc. Succinylcholine Chloride Injection is for intramuscular and intravenous use. It is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
- 06/09/2020
|
Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
- Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Bill Peters, CFO and Dan Dischner, Vice President of Corporate Communications and Human Resources will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 4:00 p.m. Eastern Time. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
- 06/02/2020
|
Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
|
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2020 Results - Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2020 Earnings Conference Call May 07, 2020, 05:00 PM ET Company Participants Dan Dischner - VP of Corporate Com
- 05/12/2020
|
U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv
- Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on
Monday.
HIGHLIGHTS
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Equity Residential : Evercore ISI raises to in-line from underperform
* Fiserv Inc : Keybanc raises target price to $115 from $108
* GTT Communications Inc : SunTrust Robinson cuts to hold from buy
* UDR Inc : Evercore ISI raises to in-line from underperform
Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order.
* Abbvie Inc : SVB Leerink raises price target to $122 from $107
* Accelerate Diagnostics Inc : Piper Sandler cuts target price to $14 from $16
* Acushnet Holdings Corp : Compass Point raises TP to $22.25 from $21.50
* Acushnet Holdings Corp : Keybanc raises target price to $31 from $28
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Advance Auto Parts Inc : UBS raises target price to $140 from $135
* AIG : UBS cuts target price to $45 from $49
* Air Lease Corp : Deutsche Bank cuts target price to $36 from $45
* Air Lease Corp : Stephens raises target price to $36 from $30
* Airgain Inc : Northland Capital Markets raises target price to $23
* Alarm.Com Holdings Inc : Credit Suisse cuts target price to $62 from $64
* Albemarle Corp : RBC raises target price to $66 from $64
* Albemarle Corp : SunTrust Robinson cuts target price to $65 from $90
* Allegiant Travel Co : Evercore ISI cuts target price to $95 from $100
* Allscripts Healthcare Solutions : Canaccord Genuity cuts TP to $11 from $13
* Amdocs Ltd : Citigroup cuts price target to $76 from $83
* Amedisys Inc : Raymond James cuts price target to $210 from $225
* Amedisys Inc : UBS cuts target price to $190 from $208
* American Axle & Manufacturing Holdings : Citigroup raises TP to $7.5 from $6
* American Axle & Manufacturing Holdings : RBC raises target price to $7 from $5
* American Homes 4 Rent : Evercore ISI raises target price to $27 from $25
* Ameriprise Financial Inc : RBC raises target price to $155 from $145
* Amerisourcebergen Corp : Deutsche Bank raises target price to $98 from $93
* Amphastar Pharmaceuticals Inc : BMO raises price target to $21 from $20
* Angi Homeservices Inc : Citigroup raises price target to $10 from $6.5
* Aon Plc : Citigroup cuts price target to $230 from $240
* Aon Plc : KBW raises target price to $192 from $184
* Aon Plc : UBS cuts target price to $197 from $202
* Apache Corp : CFRA cuts to sell from hold; raises price target to $9
* Apache Corp : MKM Partners cuts target price by $1 to $19
* Aptiv Plc : Benchmark cuts price target to $87 from $90
* Arch Capital Group Ltd : UBS cuts target price to $39 from $43
* Atara Biotherapeutics Inc : Jefferies cuts target price to $11 from $13
* Athene Holding Ltd : BMO cuts price target to $60 from $63
* Atricure Inc : BTIG raises target price to $56 from $45
* Atricure Inc : Needham raises target price to $63 from $49
* Atricure Inc : Oppenheimer raises price target to $52 from $45
* Atricure Inc : SVB Leerink raises price target to $55 from $50
* Autonation Inc : CFRA cuts price target by $10 to $50
* Avalonbay Communities Inc : Evercore ISI cuts target price to $181 from $189
* Avista Corp : Guggenheim cuts target price to $38 from $39
* Bain Capital Specialty Finance : Citigroup raises price target to $10 from $7.5
* Ball Corp : Citigroup cuts price target to $86 from $89
* Ball Corp : Northland Capital Markets cuts target price to $80
* Baudax Bio Inc : Oppenheimer cuts price target to $14 from $16
* Bellring Brands Inc : Stifel cuts target price to $23 from $25
* BJ's Restaurants Inc : Deutsche Bank raises target price to $27 from $26
* Bloomin' Brands Inc : BMO raises price target to $10 from $9
* Bloomin' Brands Inc : Deutsche Bank raises target price to $15 from $14
* Bloomin' Brands Inc : Guggenheim raises target price to $15 from $11
* Bloomin' Brands Inc : Raymond James cuts target price to $14 from $15
* BP Midstream Partners LP : Mizuho raises target price to $14 from $13
* Broadridge Financial Solutions : Piper Sandler cuts TP to $120 from $124
* Broadridge Financial Solutions : Rosenblatt Securities ups TP to $115 from $101
* Brookfield Infrastructure Partners LP : BMO raises price target to $46 from $45
* Brookfield Infrastructure Partners LP : Scotiabank cuts Tp to $50 from $51
* Brookfield Property Partners LP : Canaccord Genuity cuts TP to $12 from $13
* Brookfield Property Partners LP : CIBC cuts target price to $18 from $20.50
* Brookfield Property Partners LP : RBC cuts target price to $18 from $22
* Bruker Corp : BTIG cuts price target to $50 from $57
* Cabot Oil & Gas Corp : Tudor Pickering Holt cuts to hold from buy
* Calithera Biosciences Inc : Citigroup raises price target to $10 from $7
* Callaway Golf Co : >: Compass Point cuts target price to $17.50 from $20
* Callaway Golf Co : Compass Point cuts target price to $17.50 from $20
* Camden Property Trust : Evercore ISI cuts target price to $98 from $102
* Camden Property Trust : Stifel raises target price to $96 from $91
* Cardtronics Plc : D.A. Davidson cuts target price to $34 from $40
* Cardtronics Plc : SunTrust Robinson raises target price to $29 from $23
* Cargurus Inc : RBC raises target price to $25 from $22
* Carnival : HSBC raises to buy from hold; cuts target price to $15.9 from $45.3
* Carrier Global Corp : Citigroup raises price target to $20 from $17
* Carvana Co : Oppenheimer raises price target to $127 from $95
* Carvana Co : Oppenheimer raises target price to $127 from $95
* Casella Waste Systems Inc : Jefferies raises target price to $56 from $52
* Casella Waste Systems Inc : Raymond James raises target price to $56 from $49
* Casella Waste Systems Inc : Stifel raises target price to $47 from $45
* Cellectis : Citigroup cuts price target to $15 from $16
* Centurylink Inc : SunTrust Robinson cuts target price to $9 from $10
* Ceridian Hcm Holding Inc : Jefferies raises target price to $65 from $60
* Chevron Corp : Independent Research raises target price to $98 from $90; hold
* CNX Resources Corp : Tudor Pickering Holt cuts to hold from buy
* Cognizant Technology Solutions : Evercore ISI cuts target price to $53 from $55
* Cognizant Technology Solutions Corp : HSBC cuts target price to $56 from $70
* Coherus Biosciences Inc : Citigroup cuts price target to $30 from $31
* Conagra Brands Inc : SunTrust Robinson cuts to hold from buy
* Consolidated Edison Inc : Evercore ISI cuts target price to $85 from $86
* Continental Resources : TD Securities raises target price to $14.50 from $13.50
* Cooper Tire & Rubber Co : JP Morgan cuts target price to $29 from $30
* Corporate Office Properties Trust : SunTrust Robinson raises TP to $28 from $26
* Corteva Inc : RBC raises target price to $31 from $27
* Covanta Holding : Stifel raises to hold from sell; raises TP to $9.50 from $6.50
* Crocs Inc : Piper Sandler raises target price to $28 from $24
* Cross Country Healthcare Inc : BMO cuts price target to $8 from $11
* Cryoport Inc : Stephens raises target price to $23 from $21
* CVR Energy Inc : Credit Suisse raises target price to $19 from $16
* Cytomx Therapeutics Inc : Wedbush raises target price to $16 from $11
* Danaher Corp : Evercore ISI raises target price to $175 from $150
* Danaher Corp : RBC raises target price to $173 from $159
* Datadog Inc : RBC raises target price to $50 from $43
* Dentsply Sirona : Barrington Research cuts to market perform from outperform
* Dentsply Sirona Inc : UBS cuts target price to $44 from $59
* Dicerna Pharmaceuticals : SunTrust Robinson raises target price to $33 from $28
* Diebold Nixdorf Inc : JP Morgan raises target price to $7 from $6
* Diebold Nixdorf Inc : JP Morgan raises to neutral from underweight
* Discovery Inc : Rosenblatt Securities cuts price target to $24 from $27
* Dish Network Corp : RBC cuts target price to $32 from $39
* Domtar : D.A. Davidson cuts to neutral from buy; cuts TP to $26 from $44
* Domtar Corp : Scotiabank cuts target price to $29 from $30
* Domtar Corp : TD Securities raises target price to $26 from $22
* E. W. Scripps Co : Benchmark cuts target price to $15 from $24
* E. W. Scripps Co : Guggenheim raises target price to $8 from $6.50
* Edison Intl.
- 05/11/2020
|
BMO Capital Maintains Market Perform on Amphastar Pharmaceuticals, Raises Price Target to $21
|
Edited Transcript of AMPH earnings conference call or presentation 7-May-20 9:00pm GMT
- Q1 2020 Amphastar Pharmaceuticals Inc Earnings Call
- 05/11/2020
|
Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
- Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
- 05/09/2020
|
Edited Transcript of AMPH earnings conference call or presentation 7-May-20 9:00pm GMT
- Q1 2020 Amphastar Pharmaceuticals Inc Earnings Call
- 05/09/2020
|
Amphastar Pharmaceuticals Inc (AMPH) Q1 2020 Earnings Call Transcript
- All statements on this conference call that are not historical are forward-looking statements, including, among other things, statements relating to the company's expectations regarding future financial performance, backlog, sales and marketing of its products; market size and growth; the timing of FDA filings or approvals, including the DMF of ANP; the timing of product launches, acquisitions and other materials related to its pipeline of product candidates; its share buyback program and other future events such as the impact of COVID-19 pandemic and related responses of business and government to the epidemic on our operations and personnel and on commercial activity and demand across our business operations and results of operations. Words such as may, might, will, could, would, should, anticipate, predict, potential, continue, expect, intend, plan, project, believe, estimate and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words.
- 05/08/2020
|
Amphastar Pharmaceuticals Q1 Adj. EPS $0.170 Beats $0.080 Estimate, Sales $84.688M Beat $82.830M Estimate
|
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2020
- RANCHO CUCAMONGA, Calif., May 07, 2020 -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March.
- 05/07/2020
|
Why the Earnings Surprise Streak Could Continue for Amphastar (AMPH)
- Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 05/06/2020
|
Why the Earnings Surprise Streak Could Continue for Amphastar (AMPH)
|
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2020
- Amphastar Pharmaceuticals, Inc. (AMPH) announced that the Company will release results for its first quarter of 2020 ended March 31, 2020, after the market closes on Thursday, May 7th, 2020, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 9246728.
- 05/04/2020
|
Collegium Pharmaceutical (COLL) Receives a Buy from Needham
- Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $38.00. The company's shares
- 05/01/2020
|
Collegium Pharmaceutical (COLL) Receives a Buy from Needham
- Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report) today and set a price
- 05/01/2020
|
Northland Securities Keeps Their Buy Rating on Amphastar Pharmaceuticals (AMPH)
- Northland Securities analyst Tim Chiang maintained a Buy rating on Amphastar Pharmaceuticals (AMPH) today and set a price target of $23.00. The company's
- 05/01/2020
|
Northland Securities Keeps Their Buy Rating on Amphastar Pharmaceuticals (AMPH)
- Northland Securities analyst
Tim Chiang
maintained a
Buy
rating on Amphastar Pharmaceuticals (
AMPH
–
Research Report
) today and set a price target of
$23.00
. The company’s shares closed last Thursday at $16.95.
According to
TipRanks.com
, Chiang i
- 05/01/2020
|
Needham Maintains a Buy Rating on Flexion Therapeutics (FLXN)
- Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $30.00. The company's shares closed
- 04/30/2020
|
Needham Maintains a Buy Rating on Flexion Therapeutics (FLXN)
- Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN – Research Report) today and set a price
- 04/30/2020
|
Needham Thinks Aerie Pharma's Stock is Going to Recover
- Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $38.00. The company's shares closed last
- 04/30/2020
|
Needham Thinks Aerie Pharma’s Stock is Going to Recover
- Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price
- 04/30/2020
|
Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
- After Northland Securities and Wedbush gave Pacira Pharmaceuticals (NASDAQ: PCRX) a Buy rating last month, the company received another Buy, this time
- 04/30/2020
|
Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
- After Northland Securities and Wedbush gave Pacira Pharmaceuticals (NASDAQ: PCRX) a Buy rating last month, the company received another Buy,
- 04/30/2020
|
Needham & Company LLC Reiterates Hold Rating for Amphastar Pharmaceuticals (NASDAQ:AMPH)
- Amphastar Pharmaceuticals (NASDAQ:AMPH)‘s stock had its “hold” rating reaffirmed by research analysts at Needham & Company LLC in a report issued on Monday, AnalystRatings.com reports. Several other analysts have also recently commented on AMPH. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target […]
- 04/29/2020
|
Clearside Biomedical (CLSD) Gets a Hold Rating from Needham
- Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical (CLSD) today. The company's shares closed last Tuesday at $1.98. According
- 04/28/2020
|
Clearside Biomedical (CLSD) Gets a Hold Rating from Needham
- Needham analyst
Serge Belanger
maintained a
Hold
rating on Clearside Biomedical (
CLSD
–
Research Report
) today. The company’s shares closed last Tuesday at $1.98.
According to
TipRanks.com
, Belanger is a 3-star analyst with an average return of
1.
- 04/28/2020
|
Needham Reaffirms Their Hold Rating on Amphastar Pharmaceuticals (AMPH)
- In a report released today, Serge Belanger from Needham maintained a Hold rating on Amphastar Pharmaceuticals (AMPH). The company's shares closed last
- 04/27/2020
|
Needham Reaffirms Their Hold Rating on Amphastar Pharmaceuticals (AMPH)
- In a report released today,
Serge Belanger
from Needham maintained a
Hold
rating on Amphastar Pharmaceuticals (
AMPH
–
Research Report
). The company’s shares closed last Monday at $17.10.
According to
TipRanks.com
, Belanger is a 2-star analyst with
- 04/27/2020
|
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Shares Sold by Nuveen Asset Management LLC
- Nuveen Asset Management LLC lowered its stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 54.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 138,345 shares of the company’s stock after selling 165,026 shares during the period. Nuveen Asset Management LLC owned 0.29% of Amphastar […]
- 04/27/2020
|
BRIEF-Amphastar Pharmaceuticals gets FDA Approval For Epinephrine Injection
- Amphastar Pharmaceuticals Inc:
- 04/27/2020
|
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial
- Amphastar’s newly approved drug product was determined by the FDA to be therapeutically equivalent to Adrenalin® (Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial) distributed in the United States by Par Pharmaceutical, Inc. Epinephrine Injection Multiple Dose Vial is for intramuscular, subcutaneous, and intravenous use, and is indicated for emergency treatment of allergic reactions (Type 1), including anaphylaxis, and to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. Additionally, the FDA granted 180 day exclusivity to Amphastar as the first generic filer.
- 04/27/2020
|
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial
- RANCHO CUCAMONGA, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”), today announces that the...
- 04/27/2020
|
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Expected to Announce Quarterly Sales of $81.13 Million
- Brokerages forecast that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will announce sales of $81.13 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Amphastar Pharmaceuticals’ earnings, with estimates ranging from $79.80 million to $82.20 million. Amphastar Pharmaceuticals reported sales of $79.79 million in the same quarter last year, which indicates a […]
- 04/27/2020
|
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP ...
|
Collegium Pharmaceutical (COLL) Gets a Buy Rating from Needham
- Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $38.00. The company's shares
- 04/24/2020
|
Collegium Pharmaceutical (COLL) Gets a Buy Rating from Needham
- Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report) today and set a price
- 04/24/2020
|
Needham Thinks Aerie Pharma's Stock is Going to Recover
- Needham analyst Serge Belanger assigned a Buy rating to Aerie Pharma (AERI) today and set a price target of $40.00. The company's shares closed last
- 04/24/2020
|
Needham Thinks Aerie Pharma’s Stock is Going to Recover
- Needham analyst
Serge Belanger
assigned a
Buy
rating to Aerie Pharma (
AERI
–
Research Report
) today and set a price target of
$40.00
. The company’s shares closed last Thursday at $14.01, close to its 52-week low of $10.81.
According to
TipRanks.co
- 04/24/2020
|
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Forecasted to Earn Q4 2021 Earnings of $0.30 Per Share
- Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) – Piper Sandler upped their Q4 2021 earnings per share (EPS) estimates for shares of Amphastar Pharmaceuticals in a research note issued on Monday, April 20th. Piper Sandler analyst D. Amsellem now expects that the company will post earnings per share of $0.30 for the quarter, up from their previous forecast […]
- 04/24/2020
|
Zogenix (ZGNX) Receives a Buy from Needham
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Zogenix (ZGNX), with a price target of $54.00. The company's shares
- 04/23/2020
|
Zogenix (ZGNX) Receives a Buy from Needham
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Zogenix (ZGNX – Research Report), with
- 04/23/2020
|
Q2 2020 EPS Estimates for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Reduced by Analyst
- Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) – Equities research analysts at Piper Sandler cut their Q2 2020 earnings per share estimates for shares of Amphastar Pharmaceuticals in a report released on Monday, April 20th. Piper Sandler analyst D. Amsellem now anticipates that the company will earn $0.14 per share for the quarter, down from their prior forecast […]
- 04/23/2020
|
Are Robust Financials Driving The Recent Rally In Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Stock?
- Most readers would already be aware that Amphastar Pharmaceuticals' (NASDAQ:AMPH) stock increased significantly by 21...
- 04/22/2020
|
Geode Capital Management LLC Purchases 12,807 Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)
- Geode Capital Management LLC boosted its stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 504,828 shares of the company’s stock after buying an additional 12,807 shares during the period. […]
- 04/21/2020
|
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Shares Sold by Cubist Systematic Strategies LLC
- Cubist Systematic Strategies LLC reduced its stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 76.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,264 shares of the company’s stock after selling 33,193 shares during the quarter. Cubist Systematic Strategies LLC’s holdings […]
- 04/17/2020
|
Amphastar Pharmaceuticals (AMPH) Receives a Hold from Needham
- Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals (AMPH) today. The company's shares closed last Wednesday at $16.19.
- 04/16/2020
|
Amphastar Pharmaceuticals (AMPH) Receives a Hold from Needham
- Needham analyst
Serge Belanger
maintained a
Hold
rating on Amphastar Pharmaceuticals (
AMPH
–
Research Report
) today. The company’s shares closed last Wednesday at $16.19.
According to
TipRanks.com
, Belanger is a 2-star analyst with an average retu
- 04/16/2020
|
Needham Sticks to Its Hold Rating for Clearside Biomedical (CLSD)
- Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical (CLSD) today. The company's shares closed last Wednesday at $2.41.
- 04/16/2020
|
Needham Sticks to Its Hold Rating for Clearside Biomedical (CLSD)
- Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical (CLSD – Research Report) today. The company’s shares closed
- 04/16/2020
|
Needham Remains a Buy on Verrica Pharmaceuticals (VRCA)
- Needham analyst Serge Belanger maintained a Buy rating on Verrica Pharmaceuticals (VRCA) today and set a price target of $20.00. The company's shares
- 04/16/2020
|
Needham Remains a Buy on Verrica Pharmaceuticals (VRCA)
- Needham analyst
Serge Belanger
maintained a
Buy
rating on Verrica Pharmaceuticals (
VRCA
–
Research Report
) today and set a price target of
$20.00
. The company’s shares closed last Wednesday at $11.13.
According to
TipRanks.com
, Belanger is a 2-st
- 04/16/2020
|
Needham Thinks Zynerba Pharmaceuticals' Stock is Going to Recover
- Needham analyst Serge Belanger maintained a Buy rating on Zynerba Pharmaceuticals (ZYNE) today and set a price target of $16.00. The company's shares
- 04/16/2020
|
Needham Thinks Zynerba Pharmaceuticals’ Stock is Going to Recover
- Needham analyst
Serge Belanger
maintained a
Buy
rating on Zynerba Pharmaceuticals (
ZYNE
–
Research Report
) today and set a price target of
$16.00
. The company’s shares closed last Wednesday at $4.01, close to its 52-week low of $2.55.
According to
- 04/16/2020
|
BioCryst (BCRX) Gets a Hold Rating from Needham
- In a report released today, Serge Belanger from Needham maintained a Hold rating on BioCryst (BCRX). The company's shares closed last Wednesday at $2.70.
- 04/16/2020
|
Needham Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
- Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV) today and set a price target of $28.00. The company's shares
- 04/16/2020
|
Needham Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
- Needham analyst
Serge Belanger
maintained a
Buy
rating on KalVista Pharmaceuticals (
KALV
–
Research Report
) today and set a price target of
$28.00
. The company’s shares closed last Wednesday at $9.98.
According to
TipRanks.com
, Belanger is a 2-st
- 04/16/2020
|
Liquidia Technologies (LQDA) Receives a Buy from Needham
- Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA) today and set a price target of $30.00. The company's shares closed
- 04/15/2020
|
Liquidia Technologies (LQDA) Receives a Buy from Needham
- Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price
- 04/15/2020
|
Needham Keeps Their Buy Rating on Heron Therapeutics (HRTX)
- Needham analyst Serge Belanger maintained a Buy rating on Heron Therapeutics (HRTX) today and set a price target of $44.00. The company's shares closed
- 04/15/2020
|
Needham Keeps Their Buy Rating on Heron Therapeutics (HRTX)
- Needham analyst
Serge Belanger
maintained a
Buy
rating on Heron Therapeutics (
HRTX
–
Research Report
) today and set a price target of
$44.00
. The company’s shares closed last Tuesday at $14.85.
According to
TipRanks.com
, Belanger is a 1-star anal
- 04/15/2020
|
Flexion Therapeutics (FLXN) Receives a Buy from Needham
- Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $36.00. The company's shares closed
- 04/15/2020
|
Needham Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Revance Therapeutics (RVNC), with a price target of $36.00. The
- 04/15/2020
|
Needham Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
- In a report released today,
Serge Belanger
from Needham maintained a
Buy
rating on Revance Therapeutics (
RVNC
–
Research Report
), with a price target of
$36.00
. The company’s shares closed last Tuesday at $15.96.
According to
TipRanks.com
, Belang
- 04/15/2020
|
Alliancebernstein L.P. Purchases 1,400 Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)
- Alliancebernstein L.P. boosted its position in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 1.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 109,340 shares of the company’s stock after acquiring an additional 1,400 shares during the period. Alliancebernstein L.P.’s holdings in Amphastar Pharmaceuticals were worth $2,109,000 at the end of the most recent quarter. A […]
- 04/15/2020
|
Needham Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Trevi Therapeutics (TRVI), with a price target of $18.00. The company's
- 04/14/2020
|
Needham Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report),
- 04/14/2020
|
Amphastar Pharma's President bids adieu
- Amphastar Pharmaceuticals (NASDAQ:AMPH) announces that Mr. Jason B. Shandell has stepped down as President, General Counsel, and member of the Board of Directors, effective April 10. Dr. Jack Y. Zhan
- 04/14/2020
|
BRIEF-Amphastar Pharmaceuticals Inc Simplifies Management Structure
- Amphastar Pharmaceuticals Inc:
- 04/13/2020
|
Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure
|
Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure
- Mr. Jason B. Shandell has stepped down as President, General Counsel, and member of the Board of Directors, effective April 10, 2020. Mr. Shandell and the Company have mutually agreed that now is the right time to transition and to consolidate the Company’s management structure. The Company thanks Mr. Shandell for his service over the past twelve years and wishes him success in his future endeavors.
- 04/13/2020
|
Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure
- RANCHO CUCAMONGA, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a...
- 04/13/2020
|
Needham Remains a Hold on BioCryst (BCRX)
- In a report released today, Serge Belanger from Needham maintained a Hold rating on BioCryst (BCRX). The company's shares closed last Thursday at $2.07,
- 04/13/2020
|
Needham Remains a Hold on BioCryst (BCRX)
- In a report released today, Serge Belanger from Needham maintained a Hold rating on BioCryst (BCRX – Research Report). The
- 04/13/2020
|
Needham Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)
- Needham analyst Serge Belanger maintained a Buy rating on Collegium Pharmaceutical (COLL) today and set a price target of $38.00. The company's shares
- 04/13/2020
|
Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and Neurocrine (NBIX)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (AERI) and Neurocrine (NBIX) with bullish
- 04/13/2020
|
Analysts Offer Insights on Healthcare Companies: Aerie Pharma (NASDAQ: AERI) and Neurocrine (NASDAQ: NBIX)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (
AERI
–
Research Report
) and Neurocrine (
NBIX
–
Research Report
) with bullish sentiments.
Aerie Pharma (AERI)
Needham analyst
Serge Belang
- 04/13/2020
|
Stocks To Watch: Big Banks And Vaccine Players In The Spotlight
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 04/11/2020
|
Amphastar Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference
- Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 12:50 p.m. Eastern Time. This presentation will be made available with a live webcast
- 04/09/2020
|
Amphastar Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference
- RANCHO CUCAMONGA, April 09, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and...
- 04/09/2020
|
AQR Capital Management LLC Sells 1,567 Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)
- AQR Capital Management LLC lessened its stake in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 3.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 38,568 shares of the company’s stock after selling 1,567 shares during the period. AQR Capital Management LLC owned about 0.08% of Amphastar […]
- 04/09/2020
|
Liquidia Technologies (LQDA) Gets a Buy Rating from Needham
- Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA) today and set a price target of $30.00. The company's shares closed
- 04/08/2020
|
Liquidia Technologies (LQDA) Gets a Buy Rating from Needham
- Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price
- 04/08/2020
|
Needham Remains a Buy on KalVista Pharmaceuticals (KALV)
- Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV) today and set a price target of $28.00. The company's shares
- 04/07/2020
|
Needham Remains a Buy on KalVista Pharmaceuticals (KALV)
- Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price
- 04/07/2020
|
We Wouldn’t Rely On Amphastar Pharmaceuticals’s (NASDAQ:AMPH) Statutory Earnings As A Guide
- Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
- 04/07/2020
|
Head-To-Head Analysis: Amphastar Pharmaceuticals (NASDAQ:AMPH) and Neurotrope (NASDAQ:NTRP)
- Amphastar Pharmaceuticals (NASDAQ:AMPH) and Neurotrope (NASDAQ:NTRP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability. Risk and Volatility Amphastar Pharmaceuticals has a beta of 1.11, meaning that its stock price is […]
- 04/07/2020
|
Needham Thinks GW Pharma's Stock is Going to Recover
- In a report released today, Serge Belanger from Needham maintained a Buy rating on GW Pharma (GWPH), with a price target of $190.00. The company's shares
- 04/06/2020
|
Needham Thinks GW Pharma’s Stock is Going to Recover
- In a report released today, Serge Belanger from Needham maintained a Buy rating on GW Pharma (GWPH – Research Report),
- 04/06/2020
|
$81.66 Million in Sales Expected for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) This Quarter
- Wall Street analysts forecast that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will report sales of $81.66 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Amphastar Pharmaceuticals’ earnings. The lowest sales estimate is $81.38 million and the highest is $82.20 million. Amphastar Pharmaceuticals reported sales of $79.79 million during the same quarter […]
- 04/04/2020
|
Needham Thinks Aerie Pharma's Stock is Going to Recover
- Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $40.00. The company's shares closed last
- 04/03/2020
|
Needham Thinks Aerie Pharma’s Stock is Going to Recover
- Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price
- 04/03/2020
|
Collegium Pharmaceutical (COLL) Receives a Buy from Needham
- Needham analyst Serge Belanger maintained a Buy rating on Collegium Pharmaceutical (COLL) today and set a price target of $38.00. The company's shares
- 04/03/2020
|
Collegium Pharmaceutical (COLL) Receives a Buy from Needham
- Needham analyst Serge Belanger maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report) today and set a price
- 04/03/2020
|
Needham Thinks Flexion Therapeutics' Stock is Going to Recover
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Flexion Therapeutics (FLXN), with a price target of $36.00. The
- 04/01/2020
|
Needham Thinks Flexion Therapeutics’ Stock is Going to Recover
- In a report released today,
Serge Belanger
from Needham maintained a
Buy
rating on Flexion Therapeutics (
FLXN
–
Research Report
), with a price target of
$36.00
. The company’s shares closed last Wednesday at $7.86, close to its 52-week low of $5.02
- 04/01/2020
|
Edited Transcript of AMPH earnings conference call or presentation 12-Mar-20 9:00pm GMT
- Q4 2019 Amphastar Pharmaceuticals Inc Earnings Call
- 03/31/2020
|
Is Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) CEO Pay Justified?
- In 1996 Jack Zhang was appointed CEO of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). This analysis aims first to...
- 03/29/2020
|
Edited Transcript of AMPH earnings conference call or presentation 12-Mar-20 9:00pm GMT
- Q4 2019 Amphastar Pharmaceuticals Inc Earnings Call
- 03/28/2020
|
Collegium Pharmaceutical (COLL) Receives a Buy from Needham
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL), with a price target of $38.00. The
- 03/27/2020
|
Collegium Pharmaceutical (COLL) Receives a Buy from Needham
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report),
- 03/27/2020
|
Needham Sticks to Their Buy Rating for Aerie Pharma (AERI)
- Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $40.00. The company's shares closed last
- 03/27/2020
|
Needham Sticks to Their Buy Rating for Aerie Pharma (AERI)
- Needham analyst
Serge Belanger
maintained a
Buy
rating on Aerie Pharma (
AERI
–
Research Report
) today and set a price target of
$40.00
. The company’s shares closed last Monday at $13.50, close to its 52-week low of $10.80.
According to
TipRanks.co
- 03/27/2020
|
Needham Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
- Needham analyst Serge Belanger maintained a Buy rating on Revance Therapeutics (RVNC) today and set a price target of $36.00. The company's shares closed
- 03/27/2020
|
Needham Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
- Needham analyst Serge Belanger maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price
- 03/27/2020
|
Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress
- Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress
- 03/25/2020
|
Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress
- Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress
- 03/25/2020
|
Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress
|
What Bargain Hunting? Tap 5 Stocks With Rising P/E
- Bet on these top-ranked stocks with rising P/E to realize outsized gains.
- 03/24/2020
|
What Bargain Hunting? Tap 5 Stocks With Rising P/E
- Bet on these top-ranked stocks with rising P/E to realize outsized gains.
- 03/24/2020
|
Great West Life Assurance Co. Can Purchases New Position in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)
- Great West Life Assurance Co. Can purchased a new stake in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 43,085 shares of the company’s stock, valued at approximately $824,000. Several other large investors have also recently made changes to their positions in AMPH. […]
- 03/24/2020
|
What Bargain Hunting? Tap 5 Stocks With Rising P/E
|
Verrica Pharmaceuticals (VRCA) Initiated with a Buy at Needham
- Verrica Pharmaceuticals (VRCA) received a Buy rating and a $20.00 price target from Needham analyst Serge Belanger today. The company's shares closed last
- 03/23/2020
|
Verrica Pharmaceuticals (VRCA) Initiated with a Buy at Needham
- Verrica Pharmaceuticals (VRCA – Research Report) received a Buy rating and a $20.00 price target from Needham analyst Serge Belanger
- 03/23/2020
|
What You Must Know About Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Beta Value
- If you're interested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), then you might want to consider its beta (a...
- 03/23/2020
|
ProShare Advisors LLC Sells 1,785 Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)
- ProShare Advisors LLC lessened its stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 10.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,956 shares of the company’s stock after selling 1,785 shares during the period. ProShare Advisors LLC’s holdings in Amphastar Pharmaceuticals […]
- 03/23/2020
|
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
- Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
- 03/20/2020
|
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
- Stabilizing prices of generic drugs have led to recovery in the industry. New launches have also provided a boost. However, coronavirus crisis creates an uncertainty for the industry.
- 03/20/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row
- After H.C. Wainwright and Mizuho Securities gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from
- 03/20/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row
- After H.C. Wainwright and Mizuho Securities gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another
- 03/20/2020
|
Needham Reaffirms Their Buy Rating on Collegium Pharmaceutical (COLL)
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL), with a price target of $38.00. The
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
Acer Therapeutics (ACER) Receives a Hold from Needham
- Needham analyst Serge Belanger maintained a Hold rating on Acer Therapeutics (ACER) today. The company's shares closed last Monday at $2.02, close to its
- 03/19/2020
|
Acer Therapeutics (ACER) Receives a Hold from Needham
- Needham analyst
Serge Belanger
maintained a
Hold
rating on Acer Therapeutics (
ACER
–
Research Report
) today. The company’s shares closed last Monday at $2.02, close to its 52-week low of $1.87.
According to
TipRanks.com
, Belanger has currently no
- 03/19/2020
|
Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 1-Year Low on Insider Selling
- Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)’s stock price hit a new 52-week low during mid-day trading on Wednesday following insider selling activity. The stock traded as low as $12.90 and last traded at $13.10, with a volume of 179006 shares. The stock had previously closed at $14.50. Specifically, CFO William J. Peters sold 4,701 shares of the […]
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) CFO Sells $65,531.94 in Stock
- Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) CFO William J. Peters sold 4,701 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $13.94, for a total value of $65,531.94. Following the completion of the sale, the chief financial officer now owns 76,011 shares of […]
- 03/18/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI) and Moderna (MRNA)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trevi Therapeutics (TRVI) and Moderna (MRNA) with bullish
- 03/16/2020
|
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (NASDAQ: TRVI) and Moderna (NASDAQ: MRNA)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trevi Therapeutics
- 03/16/2020
|
Head to Head Review: Synlogic (NASDAQ:SYBX) and Amphastar Pharmaceuticals (NASDAQ:AMPH)
- Synlogic (NASDAQ:SYBX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Volatility & Risk Synlogic has a beta of 2.54, indicating that its share price is 154% […]
- 03/16/2020
|
Zacks Investment Research Upgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) to "Buy"
- Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. The firm presently has a $16.00 target price on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 12.76% from the […]
- 03/15/2020
|
Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)
- Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals (AMPH) today. The company's shares closed last Monday at $14.19,
- 03/13/2020
|
Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)
- Needham analyst
Serge Belanger
maintained a
Hold
rating on Amphastar Pharmaceuticals (
AMPH
–
Research Report
) today. The company’s shares closed last Monday at $14.19, close to its 52-week low of $13.09.
According to
TipRanks.com
, Belanger is curr
- 03/13/2020
|
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL) and Homology Medicines (FIXX)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (COLL) and Homology Medicines
- 03/13/2020
|
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (NASDAQ: COLL) and Homology Medicines (NASDAQ: FIXX)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical
- 03/13/2020
|
Needham Keeps Their Buy Rating on Aerie Pharma (AERI)
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI), with a price target of $40.00. The company's
- 03/13/2020
|
Needham Keeps Their Buy Rating on Aerie Pharma (AERI)
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report),
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) * Abbott Laboratories (NYSE: ABT) * ABIOMED
- 03/13/2020
|
Flexion Therapeutics (FLXN) Gets a Buy Rating from Needham
- Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $36.00. The company's shares closed
- 03/13/2020
|
Flexion Therapeutics (FLXN) Gets a Buy Rating from Needham
- Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN – Research Report) today and set a price
- 03/13/2020
|
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2019 Results - Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2019 Results Conference Call March 12, 2020 05:00 PM ET Company Participants Jason Shandell - President Bill Pe
- 03/13/2020
|
Amphastar Pharmaceuticals Inc (AMPH) Q4 2019 Earnings Call Transcript
- AMPH earnings call for the period ending December 31, 2019.
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 03/12/2020
|
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates
- Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 03/12/2020
|
BRIEF-Amphastar Pharmaceuticals Reports Q4 Revenue Of $83.4 Mln
- Amphastar Pharmaceuticals Inc:
- 03/12/2020
|
Amphastar: 4Q Earnings Snapshot
- RANCHO CUCAMONGA, Calif. (AP) _ Amphastar Pharmaceuticals Inc. (AMPH) on Thursday reported a fourth-quarter loss of $1 million, after reporting a profit in the same period a year earlier. The Rancho Cucamonga, California-based company said it had a loss of 2 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, came to 7 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 5 cents per share. The specialty pharmaceutical company posted revenue of $83.4 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $80.3 million. For the year, the company reported net income of $48.9 million, or 98 cents per share, swinging to a profit in the period. Revenue was reported as $322.4 million. Amphastar shares have fallen 28% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $13.87, a decline of 43% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AMPH at https://www.zacks.com/ap/AMPH
- 03/12/2020
|
Amphastar: 4Q Earnings Snapshot
- RANCHO CUCAMONGA, Calif. (AP) _ Amphastar Pharmaceuticals Inc. (AMPH) on Thursday reported a fourth-quarter loss of $1 million, after reporting a profit in the same period a year earlier.
The Rancho Cucamonga, California-based company said it had a l
- 03/12/2020
|
Amphastar Pharmaceuticals Q4 EPS $0.07 Down From $0.13 YoY, Sales $83.4M Down From $89.69M YoY
|
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2019
- Reports Net Revenues of $83.4 Million for the Three Months Ended December 31, 2019 RANCHO CUCAMONGA, Calif., March 12, 2020 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:.
- 03/12/2020
|
Amphastar Pharmaceuticals, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 ...
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacted to its fourth-quarter results) * Centogene NV (NASDAQ: CNTG) * Tiziana Life Sciences PLC (NASDAQ
- 03/12/2020
|
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to Hold by BidaskClub
- Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday, BidAskClub reports. Several other equities research analysts have also issued reports on the stock. ValuEngine raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in […]
- 03/12/2020
|
